Technology Bundle ID
TAB-2733

Sensitive Method for Detection and Quantification of Anthrax, Bordetella pertussis, Clostridium difficile, Clostridium botulinum and Other Pathogen-Derived Toxins in Human and Animal Plasma

Linked ID
E-167-2013-0
Lead Inventors
Anne Boyer (CDC)
Co-Inventors
Conrad Quinn (CDC)
John Barr (CDC)
Renato Lins (CDC)
Zsuzsanna Kuklenyik (CDC)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
  • In vivo data available (human)
ICs
CDC
CDC research scientists have developed a method to identify and quantify the activity of pathogenic bacterial adenylate cyclase toxins by liquid chromatography tandem mass spectrometry (LC-MS/MS). Bacterial protein toxins are among the most potent natural poisons known, causing paralysis, immune system collapse, hemorrhaging and death in some cases. A useful tool for quantitative detection of specific toxin activity in clinical samples will provide insights into the kinetics of intoxication, stage of infection and present stage of pathogenesis.

This rapid, high-throughput analysis method will provide measurements that quantify the efficacy of toxin-based therapeutics and support patient management decisions during treatment. This technology is specific, ultrasensitive and can be implemented to detect toxins from a wide range of pathogenic bacteria. This method could be fabricated into a kit format to deliver to state or research laboratories for use during an anthrax emergency or for research purposes, i.e. animal studies evaluating anthrax therapeutics. This technology may be easily applied to detection/diagnosis of additional pathogenic bacterial species infections as well.

Commercial Applications
  • Detect toxins from a wide range of pathogenic bacteria
  • Biodefense, biosecurity diagnostics
Competitive Advantages
  • Presently no individual patient screening assay for anthrax-exposure is widely available; exposure is determined by public health investigation and environmental-sampling tests
  • Current tests lack sensitivity and evidence of effectiveness
  • Relatively rapid and exquisitely sensitive method for the detection and quantification of bacterial toxin activity from very small blood samples, accurately assessing exposure and infection

Request More Info

Licensing Contact:
Jeremiah David Mitzelfelt
jeremiah.mitzelfelt@nih.gov
Phone: 301-443-8518

Intellectual Properties

  • PCT Application PCT/US2011/059739
    Filed on 2011-11-08
  • US Application 13/878,378
    Filed on 2013-04-08
  • US Application 61/411,056
    Filed on 2010-11-08

Publications

Related Inventions

  • Detection And Neutralization Of Bacillis Anthracis Infection [E-203-2013-0]
  • Detection Of Anthrax Pathogenicity Factors (I-013-06, I-027-06) [E-196-2013-0]
  • HYBRIDOMA CELL LINES AND MONOCLONAL ANTIBODIES RECOGNIZING ANTHROSE SACCHARIDE OF BACILLUS ANTHRACIS [E-474-2013-0]
  • Linear Epitopes Of Anthrax Toxin Protection Antigen (PA) For Development Of Peptide Vaccine [E-158-2013-2]
  • Regulating Bacillus Anthracis Lethal Factor Activity Via An Activiating Epitope Region [E-210-2013-0]
  • USE OF DETECTOR RESPONSE CURVES TO OPTIMIZE SETTINGS FOR MATRIX ASSISTED LASER DESORPTION/IONIZATION IN MASS SPECTROSCOPY [E-157-2013-0]

Collaborations

  • Licensing Desired
Date Published
Data Source
tts
Data Source ID
TAB-2733